ARTBIO
The Senior Director, Regulatory Affairs leads and coordinates regulatory interactions and submission execution for ARTBIO’s clinical-stage radiopharmaceutical programs. This role is primarily responsible for coordinating regulatory medical writing across functions and translating research and development data into compliant regulatory communications. The position works cross-functionally to ensure high-quality submission deliverables and maintain alignment with Health Authorities.
ARTBIO is a biotechnology company developing a new class of alpha radioligand therapies to redefine cancer care. The company is building an ecosystem — from targeted radioligand drug candidates and radiochemistry to manufacturing, clinical infrastructure, and partnerships — to maximize the potential of these potent targeted therapies. ARTBIO aims to accelerate development and broaden patient access by combining precision targeting, specialized delivery, and collaborative clinical programs.
ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure
Jul 29, 2025
Jonathan Freeman, Ph.D. Joins ARTBIO as Chief Business Officer
Jan 6, 2026
Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival
Jul 29, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ARTBIO.
ARTBIO didn’t post a salary, so this is our estimate from similar listings.
From CAR-T to RLT: Enhancing Precision Oncology with ARTBIO’s Radioligands
Aug 5, 2025